Vaccine hesitancy decreases, long term concerns remain in myositis, rheumatic disease patients: A comparative analysis of the COVAD surveys

• Published in: Rheumatology (Oxford, England) Vol. 62; no. 10; p. 3291
• Main Authors: Sen, Parikshit, Naveen, R, Houshmand, Nazanin, Moghadam Kia, Siamak, Joshi, Mrudula, Saha, Sreoshy, Jagtap, Kshitij, Agarwal, Vishwesh, Nune, Arvind, Nikiphorou, Elena, Tan, Ai Lyn, Shinjo, Samuel Katsuyuki, Ziade, Nelly, Velikova, Tsvetelina, Milchert, Marcin, Parodis, Ioannis, Edgar Gracia-Ramos, Abraham, Cavagna, Lorenzo, Kuwana, Masataka, Knitza, Johannes, Makol, Ashima, Patel, Aarat, Pauling, John D, Wincup, Chris, Barman, Bhupen, Zamora Tehozol, Erick Adrian, Rojas Serrano, Jorge, La Torre, Ignacio García-De, Colunga-Pedraza, Iris J, Merayo-Chalico, Javier, Chibuzo, Okwara Celestine, Katchamart, Wanruchada, Goo, Phonpen Akawatcharangura, Shumnalieva, Russka, Chen, Yi-Ming, Hoff, Leonardo Santos, El Kibbi, Lina, Halabi, Hussein, Vaidya, Binit, Sazliyana Shaharir, Syahrul, Hasan, A T M Tanveer, Dey, Dzifa, Gutiérrez, Carlos Enrique Toro, Caballero-Uribe, Carlo Vinicio, Lilleker, James B, Salim, Babur, Gheita, Tamer, Chatterjee, Tulika, Distler, Oliver, Saavedra, Miguel A, Day, Jessica, Chinoy, Hector, Agarwal, Vikas, Aggarwal, Rohit, Gupta, Latika
• Format: Journal Article
• Language: English
• Published: England 03.02.2023
• Subjects: autoimmune disease; COVID-19 vaccines; Idiopathic Inflammatory Myopathies; registries; vaccine hesitancy; COVID-19 vaccines; vaccine hesitancy; Idiopathic Inflammatory Myopathies; registries; autoimmune disease
• ISSN: 1462-0332; 1462-0324; 1462-0332
• DOI: 10.1093/rheumatology/kead057

COVID-19 vaccines have a favorable safety profile in patients with autoimmune rheumatic diseases (AIRDs) such as idiopathic inflammatory myopathies (IIMs), however hesitancy continues to persist among these patients.Therefore, we studied the prevalence, predictors, and reasons for hesitancy in patients with IIMs, other AIRDs, non-rheumatic autoimmune diseases (nrAIDs) and healthy controls (HCs), using data from the two international COVID-19 Vaccination in Autoimmune Diseases (COVAD) e-surveys. The 1st and 2nd COVAD patient self-reported e-surveys were circulated from March to December 2021, and February to June 2022 (ongoing). We collected data on demographics, comorbidities, COVID-19 infection and vaccination history, reasons for hesitancy, and patient reported outcomes. Predictors of hesitancy were analyzed using regression models in different groups. We analyzed data from 18,882 (COVAD-1) and 7666 (COVAD-2) respondents. Reassuringly, hesitancy decreased from 2021 (16.5%) to 2022 (5.1%) [OR 0.26; 95%CI: 0.24-0.30, p < 0.001]. However, concerns/fear over long-term safety had increased [OR 3.6;95% CI:2.9-4.6, p < 0.01].We noted with concern greater skepticism over vaccine science among patients with IIMs than AIRDs [OR:1.8; 95%CI: 1.08-3.2, p = 0.023] and HCs [OR: 4; 95%CI: 1.9-8.1, p < 0.001], as well as more long-term safety concerns/fear [IIMs vs AIRDs; OR: 1.9; 95%CI: 1.2-2.9, p = 0.001; IIMs vs HCs; OR: 5.4 95%CI: 3-9.6), p < 0.001].Caucasians [OR 4.2 (1.7-10.3)] were likely to be more hesitant, while those with better PROMIS physical health score were less hesitant [OR 0.9 (0.8-0.97)]. Vaccine hesitancy has decreased from 2021 to 2022, long-term safety concerns remain among patients with IIMs, particularly in Caucasians and those with poor physical function.